RNA and Gene-Editing Therapies for Familial Chylomicronemia Syndrome

Familial chylomicronemia syndrome (FCS) is a rare but severe genetic disorder marked by extreme hypertriglyceridemia and recurrent pancreatitis. Triglyceride-lowering therapies have limited efficacy in FCS due to its lipoprotein lipase (LPL)-deficient pathophysiology. Alternatives potentially filing this gap include antisense oligonucleotide (ASO), small interfering RNA (siRNA), and gene-editing technologies. Central to these novel treatments are targets like apolipoprotein C-III (APOC3) and angiopoietin-like protein 3 (ANGPTL3), key modulators of triglyceride metabolism. Take this quiz to assess your understanding of these emerging mechanisms and their therapeutic implications.

©2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.